title: Hormone replacement therapy after endometrial cancer.
abstract: Endometrial cancer is the fourth most common female cancer in the UK and the most common gynaecological cancer. Quality of life and symptom control needs to be considered in women who enter a surgically induced menopause. Hormone replacement in this population has been controversial to date. The current evidence regarding the safety of estrogen only and combined hormone replacement therapy is discussed in this review. The use of topical vaginal therapies, alternate therapies and the current data regarding testosterone use for symptom control is also outlined.
authors.affiliation: Department of Gynaecology, St Michaels Hospital, Bristol BS2 8EG, UK.
authors.forename: K
authors.initials: K
authors.lastname: Manley
authors.forename: K
authors.initials: K
authors.lastname: Edey
authors.forename: J
authors.initials: J
authors.lastname: Braybrooke
authors.forename: J
authors.initials: J
authors.lastname: Murdoch
mesh_terms: D000728:Androgens / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000601:surgery*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D008594:Menopause, Premature / Q000187:drug effects*; D013739:Testosterone / Q000627:therapeutic use; D014622:Vaginal Creams, Foams, and Jellies / Q000627:therapeutic use
chemical_list: D000728:Androgens; D004967:Estrogens; D014622:Vaginal Creams, Foams, and Jellies; D013739:Testosterone